Showing 3791-3800 of 5773 results for "".
- Johnson & Johnson Vision Appoints Peter Menziuso as Company Group Chairmanhttps://modernod.com/news/johnson-johnson-vision-appoints-peter-menziuso-as-company-group-chairman/2480835/Johnson & Johnson Vision announced the appointment of Peter Menziuso as Company Group Chairman.
- Stoke Therapeutics Presents New In-Vivo Data Demonstrating Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002https://modernod.com/news/stoke-therapeutics-presents-new-in-vivo-data-demonstrating-dose-related-target-engagement-and-opa1-protein-upregulation-in-retinal-tissue-following-administration-of-stk-002/2480831/Stoke Therapeutics announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002. Target engagement and OPA1 protein increases were sus
- Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous Anti-VEGF Wet AMD and DME Candidatehttps://modernod.com/news/ashvattha-therapeutics-presents-phase-1-safety-data-in-healthy-subjects-for-subcutaneous-anti-vegf-wet-amd-and-dme-candidate/2480829/Ashvattha Therapeutics announced the presentation of safety data from a phase 1 study of its lead candidate D-4517.2, a VEGFR/PDGFR tyrosine kinase inhibitor conjugated to a hydroxyl dendrimer, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in
- Funding Awarded to Ophthalmologists Using Big Data to Improve Patient Carehttps://modernod.com/news/funding-awarded-to-ophthalmologists-using-big-data-to-improve-patient-care/2480828/The American Academy of Ophthalmology announced recipients of the 2021
- RetinAI Receives FDA Clearance for Discovery Image Management Platform for Ophthalmologyhttps://modernod.com/news/retinai-receives-fda-clearance-for-discovery-image-management-platform-for-ophthalmology/2480826/RetinAI Medical AG announced it has received FDA 510(k) clearance for RetinAI Discovery, the company’s image and data management platform for interoperability across the clinical and clinical study ecosystems in ophthalmology. The Discovery platform can be
- Nicox Presents Phase 2 Results on NCX 4251 and New Nonclinical Evidence of Improved Hemodynamic and Retinal Cell Physiology on NCX 470https://modernod.com/news/nicox-presents-phase-2-results-on-ncx-4251-and-new-nonclinical-evidence-of-improved-hemodynamic-and-retinal-cell-physiology-on-ncx-470/2480822/Nicox SA announced poster presentations highlighting the effect of NCX 4251 in patients with dry eye disease as well as new nonclinical evidence of neuroprotective activity on NCX 470 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 annual meeting, one of the key scien
- Verana Health Report Shows a More Than 80% Glaucoma Surgery Uptake Over 8-Year Periodhttps://modernod.com/news/verana-health-unveils-annual-ophthalmic-industry-report-that-shows-a-more-than-80-glaucoma-surgery-uptake-over-8-year-period-1/2480818/Verana Health announced the release of its American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Industry Report for 2021 at the ASCRS annual meeting. The report provides 8 years of detailed ophthalmic insights generated through analysis of the data contained i
- Allergan to Present New Data from its Portfolio of Eye Care Treatments at ARVOhttps://modernod.com/news/allergan-to-present-new-data-from-its-portfolio-of-eye-care-treatments-at-arvo/2480817/Allergan announced that it will present new data on Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only FDA-approved eye drop for the treatment of presbyopia (age-related blurry near vision) in adults, and Durysta (bimatoprost
- New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at ARVOhttps://modernod.com/news/new-data-on-potential-of-opus-aav-based-gene-therapies-for-rare-inherited-retinal-diseases-to-be-presented-at-arvo/2480815/Opus Genetics announced that data from two preclinical studies evaluating the potential of its gene therapies OPGx-001 and OPGx-002 to address forms of Leber congenital amaurosis (LCA) due to mutations of LCA5 or RDH12 genes, respectively, will b
- Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During ARVOhttps://modernod.com/news/bausch-lomb-will-present-new-scientific-data-and-analyses-on-products-and-pipeline-programs-during-arvo/2480814/Bausch + Lomb announced the presentation of 13 scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in Denver, Colorado, from May 1-4, 2022, and virtually from May 11-12, 2022. The presentations incl